Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.83 CAD
Change Today -0.01 / -0.54%
Volume 43.4K
NTB On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
Toronto
As of 12:53 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

545 Promenade du Centropolis

Suite 100

Laval, QC H7T 0A3

Canada

Phone: 450-687-2262

Fax: 450-687-2272

Neptune Technologies & Bioressources Inc., a biotechnology company, is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, or PUFAs. The company principally sells omega-3 PUFAs as bulk oil to distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO) The company’s primary products, NKO and EKO, generally come in capsule form, serve as a dietary supplement to consumers and are available at several major retailers under distributors’ private labels. Its elevated content in phospholipids rich in omega-3 and omega-9 fatty acids and antioxidants such as astaxanthin and vitamin A and vitamin E offers a product free of preservatives with clinically proven health benefits. NKO is the krill oil product providing clinically proven health benefits in the areas of cardiovascular, joint, cognitive and women’s health. Other Nutraceutical Products New Formulation Derived from NKO In addition to NKO and EKO, the company is also working on new formulations derived from NKO that target more specific conditions, including NKO Beat, which targets heart and circulation issues, NKO Flex, which targets bone and joint issues, and NKO Focus, which targets brain and vision issues. Neptune Krill Aquatein (NKA) NKA is a product that features a range of marine amino acids, including the eight essential amino acids. NKA contains pre-digested proteins that are an important source of short-chain amino acids in the form of peptides that facilitate digestion by more effective assimilation. Pharmaceutical Products and Product Candidates—Acasti The company’s subsidiary, Acasti, focuses on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases. CaPre Acasti’s primary prescription drug candidate is CaPre, which is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. The active ingredient of CaPre is a mixture of concentrated omega-3 fatty acids purified from crude krill oil and developed as an oral formulation. CaPre contains EPA and DHA bound to phospholipids, as well as free EPA and DHA for a total concentration of approximately two-thirds phospholipids and approximately 30% EPA and DHA. CaPre is designed to be used as a therapy in conjunction with positive lifestyle changes and administered either alone or in conjunction with other treatment regiments such as statins (a class of drug used to reduce cholesterol levels) and potentially for use by statin-intolerant or statin-resistant patients. In addition to targeting the reduction of hypertriglyceridemia and severe hypertriglyceridemia, nonclinical and preliminary clinical data collected by Acasti to date has indicated that CaPre may also normalize blood lipids by reducing LDL (bad cholesterol) and very low density lipoprotein while increasing HDL (good cholesterol). Acasti initiated two Phase II clinical trials in Canada (the TRIFECTA trial and the COLT trial), one of which, the COLT trial, has now been completed. Both trials were designed to evaluate the safety and efficacy of CaPre for the management of hypertriglyceridemia and severe hypertriglyceridemia and aim to evaluate the effect of different daily doses of CaPre on patients with hypertriglyceridemia to severe hypertriglyceridemia. ONEMIA ONEMIA, a medical food and Acasti’s only commercialized product to date, is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phopholipids, EPA and DHA content than CaPre. In 2012, Acasti made its first sales of ONEMIA to a medical food distributor in the United States, which began distribution of ONEMIA through its network of dispensing physicians under its own brand name. ONEMIA is also available behind-the-counter in

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NTB:CN C$1.83 CAD -0.01

NTB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apator SA 45.16 PLN +1.16
Badger Meter Inc $62.85 USD +0.31
Enzymotec Ltd $8.98 USD -0.01
Itron Inc $35.02 USD -0.25
Targeted Medical Pharma Inc $0.11 USD -0.0899
View Industry Companies
 

Industry Analysis

NTB

Industry Average

Valuation NTB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.0x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEPTUNE TECH & BIORESSOURCES, please visit www.neptunebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.